Unlike other malignancies, breast cancer is considered a heterogenous disease consisting of at least four molecular subtypes, namely luminal A, luminal B, HER2, and triple negative (or basal-like) subtypes, which are determined on the basis of hormone receptor status and HER2 expression (Yeo et al., 2014). This evidence concerns the gene ERBB2 and breast carcinoma.